| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 7.15 |
| PI3K/AKT activation | R-HSA-198203 | 6.32 |
| Cellular Senescence | R-HSA-2559583 | 5.7 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 6.77 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 6.96 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.62 |
| Immune System | R-HSA-168256 | 2.37 |
| Signaling by Rho GTPases | R-HSA-194315 | 4.43 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.37 |
| Cell Cycle, Mitotic | R-HSA-69278 | 4.16 |
| GAB1 signalosome | R-HSA-180292 | 6.31 |
| Cell Cycle | R-HSA-1640170 | 3.89 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.7 |
| Adaptive Immune System | R-HSA-1280218 | 3.19 |
| Disease | R-HSA-1643685 | 3.33 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 4.95 |
| RHO GTPases activate CIT | R-HSA-5625900 | 8.98 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 6.85 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 6.37 |
| DNA Replication | R-HSA-69306 | 6.25 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.37 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 6.37 |
| Cellular responses to stress | R-HSA-2262752 | 4.56 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 7.15 |
| G1 Phase | R-HSA-69236 | 7.73 |
| DAP12 interactions | R-HSA-2172127 | 4.56 |
| Cyclin D associated events in G1 | R-HSA-69231 | 7.73 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.59 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 7.15 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 7.18 |
| Cell Cycle Checkpoints | R-HSA-69620 | 5.64 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
| Synthesis of DNA | R-HSA-69239 | 6.37 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
| Mitotic G1-G1/S phases | R-HSA-453279 | 5.91 |
| Signaling by FGFR | R-HSA-190236 | 4.67 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 6.56 |
| Diseases of signal transduction | R-HSA-5663202 | 4.89 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 |
| Removal of licensing factors from origins | R-HSA-69300 | 6.81 |
| Innate Immune System | R-HSA-168249 | 3.17 |
| Orc1 removal from chromatin | R-HSA-68949 | 6.85 |
| Signaling by SCF-KIT | R-HSA-1433557 | 4.73 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
| DAP12 signaling | R-HSA-2424491 | 4.64 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 9.28 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 6.37 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 8.4 |
| Signaling by EGFR | R-HSA-177929 | 4.59 |
| NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
| RHO GTPase Effectors | R-HSA-195258 | 4.94 |
| S Phase | R-HSA-69242 | 6.02 |
| Signalling by NGF | R-HSA-166520 | 4.23 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 6.94 |
| G1/S Transition | R-HSA-69206 | 6.21 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 6.37 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 7.08 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.37 |
| Regulation of DNA replication | R-HSA-69304 | 6.75 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
| Signaling by PDGF | R-HSA-186797 | 4.53 |
| Signal Transduction | R-HSA-162582 | 1.78 |
| Downstream signal transduction | R-HSA-186763 | 4.65 |